The Myeloproliferative Neoplasms Channel on VJHemOnc is an independent medical education platform, supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2022 | Summit study: safety & efficacy of bezuclastinib in patients with nonadvanced systemic mastocytosis
Prithviraj Bose, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, shares some insights into the ongoing Summit study (NCT05186753), which is evaluating the safety and efficacy of bezuclastinib, a potent KIT D816V inhibitor, in adult patients with nonadvanced systemic mastocytosis (NonAdvSM). Dr Bose highlights the advantages of this agent, including its high selectivity to the target and minimal interaction with the blood-brain barrier (BBB). These features may allow bezuclastinib to inhibit KIT D816V while minimizing adverse events (AEs) in the central nervous system (CNS) as well as off-target AEs. This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
NS Pharma: Research Funding; Morphosys: Honoraria, Research Funding; Kartos: Honoraria, Research Funding; Sierra Oncology: Honoraria; Karyopharm: Honoraria; Ionis: Research Funding; Incyte: Honoraria, Research Funding; CTI BioPharma: Honoraria, Research Funding; PharmaEssentia: Honoraria; Cogent: Honoraria, Research Funding; Blueprint: Honoraria, Research Funding; BMS: Honoraria, Research Funding; AbbVie: Honoraria; Promedior: Research Funding.
